mRNA Cancer Vaccine Developed with AI Passes Phase 3 Trials: Moderna Shares Soar 140%
Moderna’s AI-designed cancer vaccine successfully completed its phase 3 clinical trials against advanced melanoma. The biotechnology company created an individualized mRNA treatment that trains the human immune system to target and destroy tumor cells.
Previously, identifying specific mutations required months of laboratory analysis, which hindered timely clinical interventions. Now, once medical teams extract tumor samples, neural networks rapidly evaluate thousands of potential neoantigens to select the 34 most effective targets for a single dose.
Global markets responded immediately to the clinical report, driving Moderna shares up by 140% in a single trading session. Industry analysts emphasize that combining machine learning with messenger RNA technology establishes a new clinical standard for personalized oncology.
